Novartis tried to undermine publicly funded trials of Avastin in AMD, says BMJ
This article was originally published in Scrip
In the latest round of the sparring over whether Roche's Avastin (bevacizumab) should be used off-label in place of Novartis's more expensive Lucentis (ranibizumab) in wet age-related macular degeneration, the British Medical Journal has published a series of articles suggesting that Novartis hindered UK public clinical trials comparing the two drugs in order to maintain sales of Lucentis.
You may also be interested in...
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.
France has announced a number of emergency measures to protect drug supplies threatened by the spread of the coronavirus.
A number of countries are resorting to extreme measures such as export bans to preserve stocks of medicines for the COVID-19 pandemic. Belgium is among the latest to impose an export prohibition, but might it fall foul of the EU’s export regulations?